Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
5.
Am J Clin Dermatol ; 22(6): 837-851, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34287768

RESUMO

Topical corticosteroid phobia may lead to poor adherence, resulting in persistent disease and escalation to systemic agents. The aim of this paper was to review current literature to assess topical steroid phobia prevalence, populations most at risk, reasons behind steroid phobia, and interventions to reduce it. A systematic search of PubMed, Ovid (Journals@Ovid, MEDLINE), ScienceDirect, and Web of Science was performed. Studies ranged from May 2000 to February 2021. In total, 37 articles met the inclusion criteria. There was inter-study variation in the way steroid phobia is defined, from concern to irrational fear. The worldwide prevalence of topical steroid phobia ranges from 31 to 95.7% and does not differ with patient race/ethnicity or dermatological condition. Female patients and caregivers, and those who have experienced side effects of topical corticosteroids are most likely to express steroid phobia. Reasons for steroid phobia include lack of education, fear of side effects, polypharmacy, misinformation, negative experience with topical steroids, and frequently changing of clinics. Successful interventions to address steroid phobia include patient education in the form of educational videos followed by individualized oral education based on concerns, and demonstrations of application of topical steroids. Multiple interventions address topical corticosteroid phobia and improve adherence of topical corticosteroids in the management of dermatological conditions. Providers should screen patients for steroid phobia, especially in populations particularly at risk. Interventions using patient education should be individualized based on concerns expressed during screening. Further research should investigate if reducing steroid phobia can in fact improve long-term adherence.


Assuntos
Fármacos Dermatológicos/efeitos adversos , Glucocorticoides/efeitos adversos , Educação de Pacientes como Assunto/métodos , Transtornos Fóbicos/epidemiologia , Dermatopatias/tratamento farmacológico , Administração Cutânea , Fármacos Dermatológicos/administração & dosagem , Glucocorticoides/administração & dosagem , Humanos , Adesão à Medicação/psicologia , Transtornos Fóbicos/diagnóstico , Transtornos Fóbicos/etiologia , Transtornos Fóbicos/prevenção & controle , Prevalência , Fatores de Risco , Dermatopatias/imunologia
9.
J Drugs Dermatol ; 15(6): 789-90, 2016 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-27272092

RESUMO

Betel quid is a drug used in Far East Asia, India, and the South Pacific. The habit of betel quid chewing is widely reported to cause oral cancer and tooth and gum disease. However, skin disease due to betel quid use is underreported. We report a case of irritant contact dermatitis to betel quid components in a 35-year-old male betel quid user who presented for evaluation of a persistent rash on his fingertips.


Assuntos
Areca/efeitos adversos , Citrus aurantiifolia/efeitos adversos , Dermatite de Contato/diagnóstico , Sucos de Frutas e Vegetais/efeitos adversos , Mãos/patologia , Folhas de Planta/efeitos adversos , Adulto , Dermatite de Contato/etiologia , Humanos , Masculino
10.
Pediatr Emerg Care ; 31(8): 586-8, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26241712

RESUMO

Eczema herpeticum is an easily missed entity most commonly seen in the pediatric population and carries the risk of systemic compromise and a 10% mortality rate. Clinicians should maintain high clinical suspicion when encountering children or young adults with a history of atopic dermatitis or other erosive dermatoses and who present with vesicular lesions, punched-out erosions, and systemic symptoms. We present 3 severe cases of eczema herpeticum that were potentially overlooked and demonstrate the need for elevated awareness to avoid potential pitfalls.


Assuntos
Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Erupção Variceliforme de Kaposi/diagnóstico , Adolescente , Pré-Escolar , Exantema , Feminino , Humanos , Lactente , Erupção Variceliforme de Kaposi/tratamento farmacológico , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...